Phio Pharmaceuticals Corp.
PHIO
$2.36
-$0.04-1.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1.64M | 1.62M | 1.64M | 2.80M | 2.85M |
| Gross Profit | -1.64M | -1.62M | -1.64M | -2.80M | -2.85M |
| SG&A Expenses | 3.67M | 3.74M | 3.82M | 3.84M | 3.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.05M | 7.39M | 7.49M | 8.67M | 9.31M |
| Operating Income | -7.05M | -7.39M | -7.49M | -8.67M | -9.31M |
| Income Before Tax | -6.77M | -7.15M | -7.42M | -8.68M | -9.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.77 | -7.15 | -7.42 | -8.68 | -9.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.77M | -7.15M | -7.42M | -8.68M | -9.38M |
| EBIT | -7.05M | -7.39M | -7.49M | -8.67M | -9.31M |
| EBITDA | -7.05M | -7.39M | -7.47M | -8.65M | -9.26M |
| EPS Basic | -7.00 | -7.06 | -11.30 | -20.01 | -29.66 |
| Normalized Basic EPS | -4.37 | -4.41 | -6.82 | -12.27 | -18.30 |
| EPS Diluted | -7.00 | -7.06 | -11.30 | -20.01 | -29.66 |
| Normalized Diluted EPS | -4.37 | -4.41 | -6.82 | -12.27 | -18.30 |
| Average Basic Shares Outstanding | 6.94M | 7.22M | 6.41M | 5.70M | 5.38M |
| Average Diluted Shares Outstanding | 6.94M | 7.22M | 6.41M | 5.70M | 5.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |